Cytochrome P450 2C9
The CYP2C9 gene encodes a member of the cytochrome P450 superfamily. It metabolizes many pharmaceuticals, including phenytoin, tolbutamide, ibuprofen and S-warfarin (phenprocoumon). With certain mutations, patients under oral anticoagulation may show an increased risk of bleeding.
Genetests:
Related Diseases:
References:
1. |
Kohn MH et al. (2000) A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans.
|
2. |
Steward DJ et al. (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3.
|
3. |
Gray IC et al. (1995) A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24.
|
4. |
Li T et al. (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation.
|
5. |
Sanderson S et al. (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.
|
6. |
King BP et al. (2004) Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.
|
7. |
Fichtlscherer S et al. (2004) Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.
|
8. |
Kirchheiner J et al. (2003) Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.
|
9. |
Williams PA et al. (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin.
|
10. |
Higashi MK et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
|
11. |
Leung AY et al. (2001) Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.
|
12. |
Xie HG et al. (2001) Molecular basis of ethnic differences in drug disposition and response.
|
13. |
Aithal GP et al. (2000) Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.
|
14. |
Thum T et al. (2000) Gene expression in distinct regions of the heart.
|
15. |
Kidd RS et al. (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.
|
16. |
Aithal GP et al. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
|
17. |
et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data.
|
18. |
Tate SK et al. (2005) Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.
|
19. |
NCBI article
NCBI 1559
|
20. |
OMIM.ORG article
Omim 601130
|
21. |
Orphanet article
Orphanet ID 241965
|
22. |
Wikipedia article
Wikipedia EN (CYP2C9)
|
Update: Aug. 14, 2020